Asensus Surgical reports Q4 revenue $5.4M; going concern; cash only through early June 2024

ASENSUS SURGICAL, INC.

Q4 2023 revenue $5.4M vs $2.5M YoY; net loss $17.2M ($0.07/share) vs $17.9M ($0.08).
Full year 2023 revenue $8.6M; 8 Senhance programs initiated; 3,550+ procedures (+13% YoY).
Cash and equivalents $21.1M at Dec 31, 2023; expects cash to sustain operations only until early June 2024.
Company will file 10-K with going concern qualification from independent auditor.
LUNA system development on track: design freeze expected H2 2024; Flex agreement for manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASENSUS SURGICAL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $8.6 million.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $8.6 million
Result: reported results

Exact text from the filing

growth of over 13% compared to 2022 ● In 2023, 8 Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems ● Full year 2023 revenue of $8.6 million ● The Company had cash, cash equivalents and short-term investments, excluding restricted cash, of approximately $21.1 million at December 31, 2023 Fourth Quarter Highlights ●

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001437749-24-009245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.